Method for evaluating blood coagulation reaction

Patent metadata

Field	Value
Publication number	US-11078518-B2
Application number	US-201314431425-A
Country	US
Kind code	B2
Filing date	Sep 26, 2013
Priority date	Sep 28, 2012
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.

First claim

The invention claimed is:

1. A method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII, wherein the method comprises:
(i) adding a blood coagulation initiation reagent comprising activated coagulation factor XI and a phospholipid to a blood-derived sample isolated from a subject, wherein the coagulation initiation reagent does not comprise tissue factor, and wherein the sample comprises the substance having an activity of substituting for coagulation factor VIII; and
(ii) measuring the amount of thrombin generated in the blood-derived sample obtained in (i),
wherein the subject is a hemorrhagic disease patient,
wherein the substance having the activity of substituting for coagulation factor VIII has been administered to the subject, and
wherein the substance having the activity of substituting for coagulation factor VIII is a bispecific antibody that binds to coagulation factor IX or activated coagulation factor IX, and to coagulation factor X.

2. The method of claim 1 wherein the hemorrhagic disease is a disease caused by decreased or deficient activity of coagulation factor VIII or activated coagulation factor VIII.

3. The method of claim 1 , wherein the hemorrhagic disease is a disease selected from the group consisting of hemophilia, acquired hemophilia, and von Willebrand's disease caused by dysfunction or deficiency of von Willebrand factor (vWF).

4. The method of claim 1 , wherein the phospholipid comprises a member selected from the group consisting of phosphatidylserine, phosphatidylcholine, phosphatidyl-ethanolamine, phosphatidylinositol, phosphatidylglycerol, diphosphatidylglycerol, and sphyngomyelin.

5. The method of claim 4 , wherein the phospholipid comprises a combination of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine.

6. The method of claim 1 , wherein the blood coagulation initiation reagent comprises the activated coagulation factor XI and phospholipid at concentrations sufficient to detect thrombin generation in a control blood-derived sample having a coagulation factor VIII activity of 1%.

7. The method of claim 1 , wherein the measuring the amount of thrombin generated comprises determining the total amount of thrombin generated.

8. The method of claim 1 , wherein measuring the amount of thrombin generated comprises determining the maximum rate of thrombin generation.

Assignees

• Chugai Pharmaceutical Co Ltd
• Public Univ Corporation Nara Medical Univ

Inventors

• Soeda Tetsuhiro
• Kitazawa Takehisa
• Shima Midori

Classifications

• G01N33/86 Primary

  involving blood coagulating time {or factors, or their receptors} · CPC title

• G01N2333/755

  Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF] · CPC title

• C12Q1/56 Primary

  involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen · CPC title

• G01N2333/96452

  Factor XI (3.4.21.27) · CPC title

• G01N2800/224

  Haemostasis or coagulation · CPC title